• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Dr. Reddy's Laboratories Ltd

    7/1/24 6:44:13 AM ET
    $RDY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RDY alert in real time by email
    SC 13D/A 1 drr0636_sc13da.htm AMENDMENT NO. 5 TO SCHEDULE 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C.  20549

     

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)*

     

    Dr. Reddy's Laboratories Limited

     (Name of Issuer)

     

    American depositary shares, each representing one equity share

     (Title of Class of Securities)

     

    256135203

     (CUSIP Number)

     

    Jonathan Gray, Esq.

    Windels Marx Lane & Mittendorf, LLP

    120 Albany Street Plaza, 6th Floor

    New Brunswick, NJ 08901

    (732) 846-7600

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    May 22, 2024

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Rule 13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No:   256135203  Page 2 of 8 Pages

     

    1.

    Names of Reporting Persons.      APS Trust

     

    S.S. or I.R.S. Identification Nos. of Above Persons (Entities Only): N/A

     

    2.

    Check the Appropriate Box if a Member of a Group

     

    (a) ¨

    (b) x

    3.

    SEC Use Only

     

    4. Source of Funds (See Instructions)

    PF
    5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

    ¨ 
    6.

    Citizenship or Place of Organization

     

    Republic of India

    Number of      
    Shares 7. Sole Voting Power 0*
    Beneficially 8. Shared Voting Power 0*  
    Owned by Each 9. Sole Dispositive Power 0*
    Reporting 10. Shared Dispositive Power 0* 
    Person With      

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0 

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    x Beneficial ownership disclaimed pursuant to Rule 13d-4

    13.

    Percent of Class Represented by Amount in Row (11)

     

    0% 

    14.

    Type of Reporting Person:

     

    OOF

     

    * On May 22, 2024, the APS Trust transferred 15,126,124 equity shares of Dr. Reddy's Laboratories Limited to Mr. K. Satish Reddy and 19,219,184 equity shares of Dr. Reddy's Laboratories Limited to Mr. G.V. Prasad. As a result, the APS Trust is no longer an owner of any equity shares of Dr. Reddy's Laboratories Limited.

     

     

     

     

    CUSIP No:   256135203  Page 3 of 8 Pages

     

    1.

    Names of Reporting Persons.      Mr. G.V. Prasad

     

    S.S. or I.R.S. Identification Nos. of Above Persons (Entities Only): N/A

     

    2.

    Check the Appropriate Box if a Member of a Group

     

    (a) ¨

    (b) x

    3.

    SEC Use Only

     

    4. Source of Funds (See Instructions)

    PF and AF
    5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

    ¨ 
    6.

    Citizenship or Place of Organization

     

    Republic of India

    Number of      
    Shares 7. Sole Voting Power 19,219,184*
    Beneficially 8. Shared Voting Power 2,543,418*
    Owned by Each 9. Sole Dispositive Power 19,219,184*
    Reporting 10. Shared Dispositive Power 2,543,418*
    Person With      

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    21,762,602

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    x Beneficial ownership disclaimed pursuant to Rule 13d-4

    13.

    Percent of Class Represented by Amount in Row (11)

     

    13.04%* 

    14.

    Type of Reporting Person:

     

    IN

      

    *On May 22, 2024, the APS Trust transferred 19,219,184 equity shares of Dr. Reddy's Laboratories Limited to Mr. G.V. Prasad. Immediately after these transfers, Mr. G.V. Prasad directly held a total of 19,219,184 equity shares of Dr. Reddy's Laboratories Limited.

     

    In addition, Mr. G.V. Prasad may be deemed to beneficially own all of the 2,543,418 equity shares of Dr. Reddy's Laboratories Limited directly held by the G.V. Prasad HUF. Mr. G.V. Prasad disclaims such beneficial ownership pursuant to Rule 13d-4.

     

     

     

     

    CUSIP No:   256135203  Page 4 of 8 Pages

     

    1.

    Names of Reporting Persons.      Mr. K. Satish Reddy

     

    S.S. or I.R.S. Identification Nos. of Above Persons (Entities Only): N/A

     

    2.

    Check the Appropriate Box if a Member of a Group

     

    (a) ¨

    (b) x

    3.

    SEC Use Only

     

    4. Source of Funds (See Instructions)

    PF and AF
    5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

    ¨ 
    6.

    Citizenship or Place of Organization

     

    Republic of India

    Number of      
    Shares 7. Sole Voting Power 16,027,126*
    Beneficially 8. Shared Voting Power 5,523,677*
    Owned by Each 9. Sole Dispositive Power 16,027,126*
    Reporting 10. Shared Dispositive Power 5,523,677*
    Person With      

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person 

     

    21,550,803*

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    x Beneficial ownership disclaimed pursuant to Rule 13d-4

    13.

    Percent of Class Represented by Amount in Row (11) 

     

    12.92%*

    14.

    Type of Reporting Person:

     

    IN

      

    *On May 22, 2024, the APS Trust transferred 15,126,124 equity shares of Dr. Reddy's Laboratories Limited to Mr. K. Satish Reddy. Immediately after these transfers, Mr. K. Satish Reddy directly held a total of 16,027,126 equity shares of Dr. Reddy's Laboratories Limited.

     

    In addition, Mr. K. Satish Reddy may be deemed to beneficially own all of the 5,523,677 equity shares of Dr. Reddy's Laboratories Limited directly held by the K. Satish Reddy HUF. Mr. K. Satish Reddy disclaims such beneficial ownership pursuant to Rule 13d-4.

     

     

     

     Page 5 of 8 Pages

     

    SCHEDULE 13D

     

    Item 1. Security and Issuer

     

    This Amendment No. 5 to Schedule 13D (this “Amendment No. 5”) further amends and supplements the Schedule 13D of Dr. Reddy's Holdings Limited (formerly Dr. Reddy's Holdings Private Limited) and Dr. K. Anji Reddy on February 15, 2002 (the “Original Schedule 13D”) with respect to the american depositary shares (“ADSs”), each representing one equity share (the “Equity Shares”), of Dr. Reddy's Laboratories Limited (the “Issuer” or the “Company”), as amended by that certain Amendment No. 1 filed on February 3, 2016 by Dr. Reddy's Holdings Limited, the APS Trust, Mr. G.V. Prasad and Mr. K. Satish Reddy (“Amendment No. 1”), and as further amended by that certain Amendment No. 2 filed on January 16, 2017 by Dr. Reddy's Holdings Limited, the APS Trust, Mr. G.V. Prasad and Mr. K. Satish Reddy (“Amendment No. 2”), and as further amended by that certain Amendment No. 3 filed on October 18, 2017 by Dr. Reddy's Holdings Limited, the APS Trust, Mr. G.V. Prasad and Mr. K. Satish Reddy (“Amendment No. 3”), and as further amended by that certain Amendment No. 4 filed on April 22, 2022, by Dr. Reddy's Holdings Limited, the APS Trust, Mr. G.V. Prasad and Mr. K. Satish Reddy (“Amendment No. 4” and, together with the Original Schedule 13D, Amendment No. 1, Amendment No. 2 and Amendment No. 3, collectively, the “Amended Schedule 13D”). The Company's principal executive offices are located at 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana 500 034, India. 

     

    This Amendment No. 5 is being filed to report the following changes: On May 22, 2024, the APS Trust transferred 15,126,124 Equity Shares to Mr. K. Satish Reddy and 19,219,184 Equity Shares to Mr. G.V. Prasad. Immediately after these transfers, the APS Trust ceased to hold any Equity Shares of the Company, Mr. K. Satish Reddy directly held a total of 16,027,126 Equity Shares of the Company and Mr. G.V. Prasad directly held a total of 19,219,184 Equity Shares of the Company.

     

    Item 2. Identity and Background

     

    Item 2 of the Amended Schedule 13D is hereby amended and supplemented as follows:

     

    (a)-(c) The persons filing this Amendment No. 5 are (i) the APS Trust, a trust formed under the laws of India; (ii) Mr. G.V. Prasad, the Co-Chairman and Managing Director of the Company; and (iii) Mr. K. Satish Reddy, Chairman of the Company. The address of each of them is 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana 500 034, India, telephone +91-40-49002900.

     

    On May 22, 2024, the APS Trust transferred 15,126,124 Equity Shares to Mr. K. Satish Reddy and 19,219,184 Equity Shares to Mr. G.V. Prasad. As a result, the APS Trust is no longer an owner of any Equity Shares of the Company.

     

    Mr. G.V. Prasad directly holds a total of 19,219,184 Equity Shares of the Company. Mr. G.V. Prasad may also be deemed to beneficially own all of the 2,543,418 Equity Shares directly held by the G.V. Prasad HUF. Mr. G.V. Prasad disclaims such beneficial ownership pursuant to Rule 13d-4.

     

    Mr. K. Satish Reddy directly holds a total of 16,027,126 Equity Shares of the Company. Mr. K. Satish Reddy may ALSO be deemed to beneficially own all of the 5,523,677 Equity Shares directly held by the K. Satish Reddy HUF. Mr. K. Satish Reddy disclaims such beneficial ownership pursuant to Rule 13d-4.

     

    (d)        The persons filing this Amendment No. 5 have not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e)        The persons filing this Amendment No. 5 have not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)         Each of Mr. G.V. Prasad and Mr. K. Satish Reddy is a citizen of the Republic of India.

     

    Item 3. Source and Amount of Funds or Other Consideration

     

    Item 3 of the Amended Schedule 13D is hereby amended and supplemented as follows:

     

    Mr. G.V. Prasad. Mr. G.V. Prasad directly holds a total of 19,219,184 Equity Shares of the Company Shares, and the source of funds for such Equity Shares are as follows:

     

     

     

     

     Page 6 of 8 Pages

     

    ·On May 22, 2024, the APS Trust transferred 19,219,184 Equity Shares to Mr. G.V. Prasad. All such Equity Shares were acquired by the APS Trust as follows:

     

    oDr. Reddy's Holdings Limited (“DRHL”) was merged out of existence (the “Merger”), with the Company as the surviving entity in the Merger, on April 22, 2022. Pursuant to the Merger, Equity Shares of the Company were issued to the shareholders of DRHL, who accordingly became direct holders of Equity Shares in the Company (equal to the number of shares that they held indirectly through DRHL immediately prior to the Merger).

     

    oThe Company issued 34,345,308 Equity Shares to the APS Trust on April 22, 2022 as consideration for the Merger.

     

    oPrior to the Merger, DRHL held 41,325,300 of the Equity Shares (after giving effect to the Company's August 30, 2006 stock split, effected as a one-for-one Equity Share divided) since prior to the effective date of the Company's registration statement on Form F-1. The source of funds for the acquisition of the remaining Equity Shares held by Dr. Reddy's Holdings Limited was funds generated from dividends on Equity Shares of the Company paid to Dr. Reddy's Holdings Limited.

     

    ·Accordingly, the foregoing is the source of funds for the 19,219,184 Equity Shares directly owned by Mr. G.V. Prasad which he acquired from the APS Trust.

     

    In addition, Mr. G.V. Prasad may be deemed to beneficially own 2,543,418 Equity Shares indirectly through the G.V. Prasad HUF. The G.V. Prasad HUF directly owns 2,543,418 Equity Shares, and the source of funds for such Equity Shares are as follows:

     

    ·Prior to the Merger, the G.V. Prasad HUF directly owned 1,117,940 Equity Shares, all of which were transferred to it by G.V. Prasad on or around March 26, 2021 for estate planning purposes. All such 1,117,940 Equity Shares were acquired by Mr. G.V. Prasad through his personal funds prior to such transfer to such HUF. An aggregate of 250,500 of such Equity Shares were acquired by him pursuant to open market transactions on stock exchanges. The remainder of such Equity Shares had been held by him since prior to the effective date of the Company's registration statement on Form F-1.

     

    ·In addition, the G.V. Prasad HUF was previously a shareholder of DRHL and, in connection with the Merger, the Company issued an additional 1,425,478 Equity Shares to the G.V. Prasad HUF on April 22, 2022 as consideration for the Merger. Accordingly, the foregoing is the source of funds for 1,425,478 of the Equity Shares directly owned by the G.V. Prasad HUF.

     

    Mr. K. Satish Reddy. Mr. K. Satish Reddy directly holds a total of 16,027,126 Equity Shares of the Company, and the source of funds for such Equity Shares are as follows:

     

    ·On May 22, 2024, the APS Trust transferred 15,126,124 Equity Shares to Mr. K. Satish Reddy. All such Equity Shares were acquired by the APS Trust pursuant to the Merger, as described under “Mr. G.V. Prasad” above. The source of funds for the 15,126,124 Equity Shares which Mr. K. Satish Reddy acquired from the APS Trust is substantially identical to the source of funds for the Equity Shares which Mr. G.V. Prasad acquired from the APS Trust, as described under “Mr. G.V. Prasad” above.

     

    ·Prior to the Merger, Mr. K. Satish Reddy directly owned 898,432 Equity Shares, all of which were acquired through his personal funds and/or funds previously borrowed from Citicorp Finance (India) Limited, as more particularly described in Item 6 of Amendment No. 2. As described in Item 1 of Amendment No. 2, 316,500 of such Equity Shares were acquired by him pursuant to open market transactions on stock exchanges. The remainder of such Equity Shares have been held by him since prior to the effective date of the Company's registration statement on Form F-1.

     

    ·In addition, Mr. K. Satish Reddy was previously a shareholder of DRHL and, in connection with the Merger, the Company issued an additional 2,570 Equity Shares to Mr. K. Satish Reddy on April 22, 2022 as consideration for the Merger. Accordingly, the foregoing is the source of funds for 2,570 of the Equity Shares directly owned by Mr. K. Satish Reddy.

     

    In addition, Mr. K. Satish Reddy may be deemed to beneficially own 5,523,677 Equity Shares indirectly through the K. Satish Reddy HUF. The K. Satish Reddy HUF directly owns 5,523,677 Equity Shares, and the source of funds for such Equity Shares are as follows:

     

    ·The K. Satish Reddy HUF was previously a shareholder of DRHL and, in connection with the Merger, the Company issued an 5,523,677 Equity Shares to the K. Satish Reddy HUF on April 22, 2022 as consideration for the Merger. Accordingly, the foregoing is the source of funds for all 5,523,677 of the Equity Shares directly owned by the K. Satish Reddy HUF.

     

     

     

     

     Page 7 of 8 Pages

     

    Item 4. Purpose of the Transaction

     

    Item 4 of the Amended Schedule 13D is hereby amended and supplemented as follows:

     

    On May 22, 2024, the APS Trust distributed all of its Equity Shares to its beneficiaries, Mr. G.V. Prasad (who received 19,219,184 Equity Shares) and Mr. K. Satish Reddy (who received 15,126,124 Equity Shares), who accordingly became direct holders of such Equity Shares. As a result, the APS Trust is no longer an owner of any Equity Shares. This transfer of shares was done as an initial step to implement family succession arrangements and planning for a smooth and streamlined transfer of family assets and businesses.

     

    Item 5. Interest in Securities of the Issuer

     

    Item 5 of the Amended Schedule 13D is hereby amended and supplemented as follows:

     

    (a)        Effective immediately after the transfer to him from the APS Trust on May 22, 2024, Mr. K. Satish Reddy directly holds a total of 16,027,126 Equity Shares of the Company. Mr. K. Satish Reddy may also be deemed to beneficially own all of the 5,523,677 Equity Shares directly held by the K. Satish Reddy HUF. Mr. K. Satish Reddy disclaims such beneficial ownership pursuant to Rule 13d-4. Collectively, Mr. K. Satish Reddy may be deemed to beneficially own Equity Shares representing approximately 12.92% of the outstanding Equity Shares of the Company.

     

    Effective immediately after the transfer to him from the APS Trust on May 22, 2024, Mr. G.V. Prasad directly holds a total of 19,219,184 Equity Shares of the Company. Mr. G.V. Prasad may also be deemed to beneficially own all of the 2,543,418 Equity Shares directly held by the G.V. Prasad HUF. Mr. G.V. Prasad disclaims such beneficial ownership pursuant to Rule 13d-4. Collectively, Mr. G.V. Prasad may be deemed to beneficially own Equity Shares representing approximately 13.04% of the outstanding Equity Shares of the Company.

     

    The APS Trust ceased to directly own any Equity Shares effective as of May 22, 2024.

     

    (b)        Mr. K. Satish Reddy has the sole power to vote or direct the vote and to dispose or to direct the disposition of the 16,027,126 Equity Shares directly held by him. Mr. K. Satish Reddy may also be deemed to share the power to vote or direct the vote and to dispose or to direct the disposition of the 5,523,677 Equity Shares directly held by the K. Satish Reddy HUF. Mr. K. Satish Reddy disclaims all such beneficial ownership pursuant to Rule 13d-4.

     

    Mr. G.V. Prasad has the sole power to vote or direct the vote and to dispose or to direct the disposition of the 19,219,184 Equity Shares directly held by him. Mr. G.V. Prasad may also be deemed to share the power to vote or direct the vote and to dispose or to direct the disposition of the 2,543,418 Equity Shares directly held by the G.V. Prasad HUF. Mr. G.V. Prasad disclaims all such beneficial ownership pursuant to Rule 13d-4.

     

    (c)        None of the reporting persons have purchased Equity Shares of the Company within the past 60 days.

     

    Item 6. Contracts, Agreements, Understandings or Relationships with Respect to Securities of the Issuer

     

    Item 6 of the Amended Schedule 13D is hereby amended and supplemented as follows:

     

    Mr. G.V. Prasad is the head of the G.V. Prasad HUF and Mr. K. Satish Reddy is the head of the K. Satish Reddy HUF. A Hindu Undivided Family (“HUF”) is a form of entity found in India among related family members. There is no written agreement governing control of the G.V. Prasad HUF or the K. Satish Reddy HUF. However, under Indian law all control of the HUF Head of the family, currently Mr. G.V. Prasad, in the case of the G.V. Prasad HUF, and Mr. K. Satish Reddy, in the case of the K. Satish Reddy HUF.

     

    Item 7. Materials to be filed as Exhibits

     

    99.1. Joint Filing Agreement of the Reporting Persons.

     

     

     

     

     Page 8 of 8 Pages

     

    AMENDMENT NO. 5 TO SCHEDULE 13D

     

    SIGNATURE

     

    After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

     

      APS Trust  
         
      By: /s/ G.V. Prasad
        Name: G.V. Prasad  
        Title:   Trustee  
           
           
      By: /s/ K. Satish Reddy  
        Name: K. Satish Reddy  
        Title:   Trustee  

     

      G.V. Prasad  
       
      By: /s/ G.V. Prasad  
           
      K. Satish Reddy  
         
      By: /s/ K. Satish Reddy  

     

    June 28, 2024

     

    Attention: Intentional misstatements or omissions of act constitute federal violations (see 18 U.S.C. 1001). 

     

     

    Get the next $RDY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RDY

    DatePrice TargetRatingAnalyst
    12/19/2024Buy → Neutral
    Nomura
    1/11/2024Buy → Underperform
    Jefferies
    8/29/2023Buy → Hold
    HSBC Securities
    5/18/2023Outperform → Mkt Perform
    Bernstein
    3/17/2023Neutral → Buy
    BofA Securities
    1/30/2023Underweight
    JP Morgan
    11/14/2022Neutral → Underperform
    Credit Suisse
    1/3/2022Neutral
    BofA Securities
    More analyst ratings

    $RDY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dr. Reddy's Q4 & Full Year FY25 Financial Results

      Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and year ended March 31, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q4FY25 FY25   Revenues ₹ 85,060 Mn ₹ 325,535 Mn [Up: 20% YoY^; 2% QoQ] [Up: 17% YoY^]     Gross Margin 55.6% 58.5% [Q4FY24: 58.6%; Q3FY25: 58.7%] [FY24: 58.6%]     SG&A Expenses ₹ 24,055 Mn ₹ 93,870 Mn [Up: 17% YoY; Flat QoQ] [Up: 22% YoY]     R&D Expens

      5/9/25 2:53:00 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

      GUANGZHOU, China and HYDERABAD, India, March 27, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as ", Dr. Reddy', s", ), announce today they have reached commercialization and license agreements for BAT2206, a proposed Stelara® biosimilar, and BAT2506, a proposed Simponi® biosimilar.

      3/27/25 11:47:00 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

      Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") and Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted a 351(k) Biologic License Application (BLA) submission for AVT03, developed by Alvotech, a proposed biosimilar of Prolia® (denosumab) and Xgeva® (denosumab). "The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients t

      3/18/25 8:35:00 AM ET
      $ALVO
      $RDY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $RDY
    Leadership Updates

    Live Leadership Updates

    See more
    • Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

      SHANGHAI, Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as ", Dr. Reddy', s", ) for the company's independently developed investigational daratumumab biosimilar HLX15, a recombinant anti-CD38 fully human monoclonal antibody injection. Dr. Reddy's will gain exclusive rights to commercialize both subcutaneous and intravenous formulation of HLX15 in a total of 43 countries and regions, comprising 42 European countries and

      2/6/25 6:35:00 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America

      Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as ", Dr. Reddy', s", )), today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America, and member of the Management Council. As part of the Dr. Reddy's senior leadership team, he will be responsible for the company's North America business and will be based out of the Princeton, New Jersey, U.S. office. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528120424/en/Milan Kalawadia (Photo: Business Wire) "I am excited to start this next chapter in my journey at Dr

      5/28/24 9:53:00 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDY
    Financials

    Live finance-specific insights

    See more
    • Dr. Reddy's Q4 & Full Year FY25 Financial Results

      Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and year ended March 31, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q4FY25 FY25   Revenues ₹ 85,060 Mn ₹ 325,535 Mn [Up: 20% YoY^; 2% QoQ] [Up: 17% YoY^]     Gross Margin 55.6% 58.5% [Q4FY24: 58.6%; Q3FY25: 58.7%] [FY24: 58.6%]     SG&A Expenses ₹ 24,055 Mn ₹ 93,870 Mn [Up: 17% YoY; Flat QoQ] [Up: 22% YoY]     R&D Expens

      5/9/25 2:53:00 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's Q3 & 9MFY25 Financial Results

      Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and nine months ended December 31, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q3FY25 9MFY25   Revenues ₹ 83,586 Mn ₹ 240,475 Mn [Up: 16% YoY^; 4% QoQ] [Up: 15% YoY^]   Gross Margin 58.7% 59.5% [Q3FY24: 58.5%; Q2FY25: 59.6%] [9MFY24: 58.6%]   SG&A Expenses ₹ 24,117 Mn ₹ 69,815 Mn [Up: 19% YoY; 5% QoQ] [Up: 23% YoY]   R&D Expenses ₹ 6,658 Mn ₹ 20,122 Mn [8.0% o

      1/23/25 12:35:00 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's Q2 & H1FY25 Financial Results

      Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) today announced its consolidated financial results for the quarter and half year ended September 30, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q2FY25 H1FY25   Revenues ₹ 80,162 Mn [Up: 17% YoY; 4% QoQ] ₹ 156,889 Mn [Up: 15% YoY]   Gross Margin 59.6% [Q2FY24: 58.7%; Q1FY25: 60.4%] 60.0% [H1FY24: 58.7%]   SG&A Expenses ₹ 23,007 Mn [Up: 22% YoY; 1% QoQ] ₹ 45,698 Mn [Up: 25% YoY]   R&D Expenses ₹ 7,271 Mn [9.1%

      11/5/24 9:59:00 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDY
    SEC Filings

    See more
    • SEC Form 6-K filed by Dr. Reddy's Laboratories Ltd

      6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)

      5/9/25 1:14:23 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Dr. Reddy's Laboratories Ltd

      6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)

      5/9/25 12:19:23 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Dr. Reddy's Laboratories Ltd

      6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)

      5/9/25 12:04:52 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dr. Reddy's downgraded by Nomura

      Nomura downgraded Dr. Reddy's from Buy to Neutral

      12/19/24 8:23:54 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's downgraded by Jefferies

      Jefferies downgraded Dr. Reddy's from Buy to Underperform

      1/11/24 8:20:29 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Reddy's downgraded by HSBC Securities

      HSBC Securities downgraded Dr. Reddy's from Buy to Hold

      8/29/23 7:17:57 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Dr. Reddy's Laboratories Ltd

      SC 13D/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)

      7/1/24 6:44:13 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Dr. Reddy's Laboratories Ltd (Amendment)

      SC 13D/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)

      5/2/22 2:44:27 PM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)

      2/2/21 7:05:59 AM ET
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care